{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:59:53Z","timestamp":1783951193443,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006251","name":"Universit\u00e9 de Bordeaux","doi-asserted-by":"publisher","award":["RRI NewMOON"],"award-info":[{"award-number":["RRI NewMOON"]}],"id":[{"id":"10.13039\/501100006251","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01232-8","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:45:33Z","timestamp":1744238733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prostate-specific membrane antigen (PSMA) expression in primary and metastatic renal cell cancer (UroCCR-65 study)"],"prefix":"10.1186","volume":"15","author":[{"given":"Salma","family":"Binzaqr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kryza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Giraudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Christophe","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokrane","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaelle","family":"Margue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9432-9223","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Morgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"1232_CR1","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.","journal-title":"Nat Rev Dis Primers"},{"key":"1232_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","volume":"70","author":"A Baccala","year":"2007","unstructured":"Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385\u201390.","journal-title":"Urology"},{"key":"1232_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13550-019-0517-6","volume":"9","author":"R Schollhammer","year":"2019","unstructured":"Schollhammer R, De Clermont Gallerande H, Yacoub M, Quintyn Ranty M-L, Barthe N, Vimont D, et al. Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples. EJNMMI Res. 2019;9:52.","journal-title":"EJNMMI Res"},{"key":"1232_CR4","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.3390\/cancers15082345","volume":"15","author":"R Schollhammer","year":"2023","unstructured":"Schollhammer R, Quintyn Ranty M-L, de Clermont Gallerande H, Cavelier F, Valverde IE, Vimont D, et al. Theranostics of primary prostate cancer: beyond PSMA and GRP-R. Cancers. 2023;15:2345.","journal-title":"Cancers"},{"key":"1232_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2967\/jnumed.117.195172","volume":"59","author":"N Woythal","year":"2018","unstructured":"Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen J-C, Huang K, et al. Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET\/CT in primary prostate cancer. J Nucl Med. 2018;59:238\u201343.","journal-title":"J Nucl Med"},{"key":"1232_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.122.263889","volume":"64","author":"R Schollhammer","year":"2023","unstructured":"Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, et al. Comparison of 68Ga-PSMA-617 PET\/CT and 68Ga-RM2 PET\/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study. J Nucl Med. 2023;64:379\u201385.","journal-title":"J Nucl Med"},{"key":"1232_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12885-023-11702-8","volume":"24","author":"D Kryza","year":"2024","unstructured":"Kryza D, Vinceneux A, Bidaux A-S, Garin G, Tatu D, Cropet C, et al. A multicentric, single arm, open-label, phase I\/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR). BMC Cancer. 2024;24:163.","journal-title":"BMC Cancer"},{"key":"1232_CR8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13058-024-01787-9","volume":"26","author":"A Heesch","year":"2024","unstructured":"Heesch A, Florea A, Maurer J, Habib P, Werth LS, Hansen T, et al. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer. Breast Cancer Res. 2024;26:30.","journal-title":"Breast Cancer Res"},{"key":"1232_CR9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.2967\/jnumed.123.265738","volume":"64","author":"SAM van Lith","year":"2023","unstructured":"van Lith SAM, Pruis IJ, Tolboom N, Snijders TJ, Henssen D, Ter Laan M, et al. PET imaging and protein expression of Prostate-Specific membrane antigen in glioblastoma: A multicenter inventory study. J Nucl Med. 2023;64:1526\u201331.","journal-title":"J Nucl Med"},{"key":"1232_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.juro.2017.08.079","volume":"199","author":"S Spatz","year":"2018","unstructured":"Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, et al. Comprehensive evaluation of prostate specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol. 2018;199:370\u20137.","journal-title":"J Urol"},{"key":"1232_CR11","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3390\/ph17121721","volume":"17","author":"K J\u00f3\u017awik-Plebanek","year":"2024","unstructured":"J\u00f3\u017awik-Plebanek K, Saracyn M, Ko\u0142odziej M, Kami\u0144ska O, Durma AD, M\u0105dra W, et al. Theranostics in renal cell Carcinoma-A step towards new opportunities or a dead End-A systematic review. Pharmaceuticals (Basel). 2024;17:1721.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1232_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.2967\/jnumed.124.267417","volume":"65","author":"MS Sadaghiani","year":"2024","unstructured":"Sadaghiani MS, Baskaran S, Gorin MA, Rowe SP, Provost J-C, Teslenko I, et al. Utility of PSMA PET\/CT in staging and restaging of renal cell carcinoma: A systematic review and metaanalysis. J Nucl Med. 2024;65:1007\u201312.","journal-title":"J Nucl Med"},{"key":"1232_CR13","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00432-022-03958-7","volume":"148","author":"L Urso","year":"2022","unstructured":"Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148:1299\u2013311.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1232_CR14","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/j.urolonc.2021.11.006","volume":"40","author":"A Tariq","year":"2022","unstructured":"Tariq A, Kwok M, Pearce A, Rhee H, Kyle S, Marsh P, et al. The role of dual tracer PSMA and FDG PET\/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urol Oncol. 2022;40:e661\u20139.","journal-title":"Urol Oncol"},{"key":"1232_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2967\/jnumed.119.234898","volume":"61","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Kobe C, Hohberg M, Zlatopolskiy BD, Krapf P, Endepols H, et al. Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med. 2020;61:729\u201334.","journal-title":"J Nucl Med"},{"key":"1232_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard J-C, Morris MA, Master V, Scott AM, et al. [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25:1277\u201387.","journal-title":"Lancet Oncol"},{"key":"1232_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2967\/jnumed.123.267175","volume":"65","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Tran B, Feldman DR, Pokorska-Bocci A, Pichereau S, Wessen J, et al. First-in-Human safety, imaging, and dosimetry of a carbonic anhydrase IX-Targeting peptide, [68Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma. J Nucl Med. 2024;65:740\u20133.","journal-title":"J Nucl Med"},{"key":"1232_CR18","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic Castration-Resistant prostate cancer. New Engl J Med. 2021;385:1091\u2013103.","journal-title":"New Engl J Med"},{"key":"1232_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"1232_CR20","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.3390\/diagnostics13193082","volume":"13","author":"D Gasparro","year":"2023","unstructured":"Gasparro D, Scarlattei M, Silini EM, Migliari S, Baldari G, Cervati V, et al. High prognostic value of 68Ga-PSMA PET\/CT in renal cell carcinoma and association with PSMA expression assessed by immunohistochemistry. Diagnostics (Basel). 2023;13:3082.","journal-title":"Diagnostics (Basel)"},{"key":"1232_CR21","doi-asserted-by":"publisher","first-page":"111218","DOI":"10.1016\/j.ejrad.2023.111218","volume":"170","author":"P Aggarwal","year":"2024","unstructured":"Aggarwal P, Singh H, Das CK, Mavuduru RS, Kakkar N, Lal A, et al. Potential role of 68Ga-PSMA PET\/CT in metastatic renal cell cancer: A prospective study. Eur J Radiol. 2024;170:111218.","journal-title":"Eur J Radiol"},{"key":"1232_CR22","unstructured":"Tariq A, Pearce A, Rhee H, Kyle S, Raveenthiran S, Pelecanos A et al. The role of Prostate-specific membrane antigen positron emission tomography\/computed tomography in primary staging of selected renal tumours: initial experience in a multicentre cohort. Eur Urol Focus. 2024;S2405-4569(23)00296-1."},{"key":"1232_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/RLU.0000000000004725","volume":"48","author":"J Zhang","year":"2023","unstructured":"Zhang J, Schuchardt C, Chen X, Baum RP. Rapid tumor washout of 177Lu-PSMA radioligand in renal cell carcinoma. Clin Nucl Med. 2023;48:732\u20134.","journal-title":"Clin Nucl Med"},{"key":"1232_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13550-024-01156-9","volume":"14","author":"TV Bogsrud","year":"2024","unstructured":"Bogsrud TV, Engelsen O, Lu TTT, Stensvold A, Johnson DR, Burkett BJ, et al. All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful. EJNMMI Res. 2024;14:95.","journal-title":"EJNMMI Res"},{"key":"1232_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2006.07.8097","volume":"25","author":"MI Milowsky","year":"2007","unstructured":"Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol. 2007;25:540\u20137.","journal-title":"J Clin Oncol"},{"key":"1232_CR26","doi-asserted-by":"publisher","first-page":"110819","DOI":"10.1016\/j.apradiso.2023.110819","volume":"197","author":"U Bauder-W\u00fcst","year":"2023","unstructured":"Bauder-W\u00fcst U, Sch\u00e4fer M, Winter R, Remde Y, Roscher M, Breyl H, et al. Synthesis of tritium-labeled Lu-PSMA-617: alternative tool for biological evaluation of radiometal-based pharmaceuticals. Appl Radiat Isot. 2023;197:110819.","journal-title":"Appl Radiat Isot"},{"key":"1232_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12020-014-0320-0","volume":"47","author":"JC Reubi","year":"2014","unstructured":"Reubi JC. Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues. Endocrine. 2014;47:659\u201361.","journal-title":"Endocrine"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01232-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01232-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T22:45:34Z","timestamp":1744238734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01232-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1232"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01232-8","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The UroCCR project (NCT03293563), which is IRB-approved and has the CNIL authorization number DR-2013-206. The UroCCR database received approval from Comit\u00e9 de Protection des Personnes Sud-Ouest et Outre-mer III (DC 2012\/108) and favorable opinion of the Comit\u00e9 Consultatif sur le Traitement de l\u2019Information en mati\u00e8re de Recherche dans le domaine de la Sant\u00e9 (CCTIRS).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}